先声药业盘中涨近6% 自研FGFR2b靶点ADC完成首例患者给药

iDoNews
21 May

5月20日,先声药业旗下先声再明宣布,其自主研发的FGFR2b靶点ADC候选药物SIM0686已启动Ⅰ期临床研究,并在南京天印山医院完成首例患者给药。受此消息影响,先声药业股价盘中上涨超7%,截至发稿涨幅为5.91%,报10.40港元,成交额达1.02亿港元。该研究针对晚期实体瘤,标志着公司在抗肿瘤创新药领域取得新进展。

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10